Dafinchi AI

Harmony Biosciences Holdings, Inc.

HRMY

Healthcare

2w

Financial Performance Summary

Cash generated from operations was approximately $79 million in the quarter, with a strong cash position of over $670 million.
Harmony Biosciences reported second quarter 2025 net revenues of $200.5 million, a 16% increase year-over-year from $172.8 million in Q2 2024.
The company extended its 4-year streak of profitability with non-GAAP adjusted net income of $53.8 million or $0.92 per diluted share, compared to $24.5 million or $0.43 per diluted share in the prior year quarter.
The financial results reflect strong underlying demand for WAKIX, offset by a slight reduction in trade inventories heading into summer months.
Total operating expenses for Q2 2025 were $114.2 million, down from $119.3 million in the same quarter last year.

Adaptive Biotechnologies Corporation

ADPT

Healthcare

1w

MRD Business Achieves Profitability and Outperforms Expectations

MRD business delivered approximately $2 million in positive adjusted EBITDA, surpassing expectations.
MRD revenue grew 42% year-over-year to $49.9 million, driven by increased clinical volume.
Test volume increased 37% YoY to over 25,300 tests, with multiple myeloma being the largest contributor at 41%.
Blood-based testing now accounts for 44% of MRD tests, up 40% YoY.
The company integrated clonoSEQ into Flatiron's OncoEMR, expanding access in community settings.
Total sequencing gross margin improved by 14 percentage points to 64%.
Cash burn was approximately $11 million, a 36% improvement YoY, with a cash position of $222 million.
Full-year guidance was raised for MRD revenue to $190-$200 million, with expectations of continued volume growth.
The company expects positive adjusted EBITDA to continue into the second half of the year.

OMCL

Healthcare

2w

Financial Performance Summary

Cash and cash equivalents were $399 million as of June 30, 2025, up from $387 million at the end of Q1 2025.
Days sales outstanding decreased by 11 days sequentially to 75 days.
Free cash flow was $27 million in Q2 2025, an increase of $17 million from the prior quarter.
GAAP earnings per share were $0.12 in Q2 2025, compared to $0.08 in Q2 2024 and a loss of $0.15 in Q1 2025.
Inventories increased by $15 million sequentially to $106 million.
Non-GAAP earnings per share for Q2 2025 was $0.45, down from $0.51 in Q2 2024 but up from $0.26 in Q1 2025.
Non-GAAP EBITDA was $38 million in Q2 2025, compared to $40 million in Q2 2024 and $24 million in Q1 2025.
Non-GAAP gross margin improved to 44.7%, up 50 basis points year-over-year and 260 basis points sequentially.
Product revenue was $163 million in Q2 2025, increasing $7 million year-over-year and $18 million sequentially.
Service revenue was $127 million in Q2 2025, up $7 million year-over-year and $3 million sequentially.
Total revenue for Q2 2025 was $291 million, up 5% year-over-year and 8% sequentially.

Integer Holdings Corporation

ITGR

Healthcare

3w

Financial Performance Summary

Adjusted earnings per share increased 19% year-over-year to $1.55.
Adjusted net income for Q2 was $55 million, up 23% year-over-year, driven by operational improvements and lower interest expense.
Adjusted operating income grew 15% year-over-year, with margin expansion of 50 basis points to 17.1%.
For the first half of 2025, sales increased 9% and adjusted operating profit increased 14%, outperforming sales growth by 1.5x.
Free cash flow in Q2 was $25 million, a 55% improvement from prior year, with $44 million cash flow from operations and $19 million CapEx.
In Q2 2025, Integer reported sales of $476 million, an 11% year-over-year increase on both reported and organic basis.
Net total debt decreased by $25 million from Q1 to $1.204 billion, with leverage at 3.2x trailing 4 quarter adjusted EBITDA.

Madrigal Pharmaceuticals, Inc.

MDGL

Healthcare

2w

Financial Performance Summary

Madrigal Pharmaceuticals reported net sales of $212.8 million in Q2 2025, a 55% increase quarter-over-quarter.
R&D expenses decreased to $54.1 million from $71.1 million year-over-year due to lower clinical trial costs.
SG&A expenses increased to $196.9 million from $105.4 million year-over-year, driven by commercial launch activities.
The company ended Q2 2025 with $802 million in cash and equivalents and secured a $500 million senior secured credit facility.
U.S. Rezdiffra net sales are annualizing at over $800 million.

Eli Lilly and Company

LLY

Healthcare

1w

Financial Performance Summary

Earnings per share increased 61% to $6.31, despite a $0.14 negative impact from acquired IPR&D charges.
Gross margin increased to 85%, up 3 percentage points year-over-year, primarily due to improved production costs and favorable product mix.
International revenue growth was strong, with Europe up 77% in constant currency, Japan up 7%, and China up 19%.
Lilly reported a 38% revenue growth in Q2 2025 compared to Q2 2024, driven by key products including Ebglyss, Jaypirca, Kisunla, Mounjaro, Omvoh, Verzenio, and Zepbound.
Marketing, selling, and administrative expenses rose 30%, and R&D expenses increased 23%, reflecting investments in new product launches and early-stage research.
Non-GAAP performance margin improved by over 6 percentage points to 45.9% of revenue.
U.S. revenue grew 38% driven by volume growth of Zepbound and Mounjaro, partially offset by an 8% price decline.